Accessibility Menu
Cg Oncology logo

Cg Oncology(NASDAQ) CGON

Market Cap$6.59BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)+100%
5 YearN/A
1 Year+178%
1 Month+8%
Premium Feature
Moneyball Superscore
70/100
$74.34
-5.91%
-4.67Today
After hours$74.32-$0.02 (-0.03%)
Cg Oncology last closing stock price
MetricPriceDate
Last closeUSD 74.342026-08-28
Cg Oncology stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.85%USD 79.812026-08-21
1 month+7.55%USD 69.122026-07-29
3 month+19.34%USD 62.292026-05-29
Year to date+79.05%USD 41.522025-12-31
1 year+178.27%USD 26.722025-08-28
Since inception+100%USD 37.172024-01-25

Cg Oncology Financials at a Glance

Market Cap

$6.59BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$6.23M

Net Income (TTM)

-$224.38M

EPS (TTM)

-$2.70

P/E Ratio

-27.58

Dividend

$0.00

Beta (Volatility)

1.48 (Average)

Price

$74.34

Volume

612,565.086

Open

$78.15

Previous Close

$74.34

Daily Range

$73.93 - $78.16

52-Week Range

$26.25 - $80.97

Estimated Earnings Date

Nov 13, 2026

CGON News

SellAlert-Purple.png

This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know

Jonathan PoncianoMar 21, 2026
SellAlert-Blue.png

CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale

Jonathan PoncianoFeb 19, 2026
Person in a lab gazing into a microscope

Why Cg Oncology Stock Rocketed 7% Higher Today

Eric VolkmanOct 8, 2025
Foolcom-Featured.png

Cg Oncology (CGON) Q2 Loss Widens 93%

Motley Fool Markets TeamAug 8, 2025

CGON: Motley Fool Moneyball Superscore

70

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cg Oncology

CG Oncology, Inc. helps people fighting bladder cancer. Its main medicine kills cancer and boosts the immune system. These treatments help patients keep their bladders after surgery.

The Cancer-Fighting Toolkit

  • Cretostimogene Monotherapy: Investigational immunotherapy for patients with high-risk bladder cancer that does not respond to standard bacterial treatments.
  • Combination Programs: Clinical trials testing the lead drug alongside other cancer therapies to improve patient outcomes.
  • Adjuvant Therapy: Treatment given after surgery to prevent cancer recurrence in patients with intermediate-risk bladder cancer.

Strategic Partnerships and Expansion

  • In Feb. 2025, the company purchased a $26.8 million note to support the acquisition of a manufacturing partner.
  • Acquired control of Biovire, a contract manufacturing organization, in July 2025 to secure drug production capabilities.
  • Established a license agreement with Kissei Pharmaceutical in March 2020 for development rights in parts of Asia.
  • Granted exclusive rights to Lepu Biotech in March 2019 to develop and sell cretostimogene in Greater China.

Why CG Oncology Stands Out

The company uses oncolytic immunotherapy, which employs modified viruses to target and destroy cancer cells specifically. By owning its primary manufacturing facility through the Biovire acquisition, the firm maintains direct control over its complex production supply chain.

Financial Performance Highlights

  • Net loss was $139.3 million for the six-month period ended June 30, 2026.
  • Cash, cash equivalents, and marketable securities totaled $1,028.3 million as of June 30, 2026.
  • Research and development expenses were $98.4 million for the six months ended June 30, 2026.
  • The company raised $391.4 million in net proceeds from selling common stock during the first half of 2026.

Bottom Line

CG Oncology has evolved from a research organization into a late-stage clinical developer with its own manufacturing assets. Its focus on versatile immunotherapy targets a high-need market for bladder-sparing treatments.

AI Generated • Aug 6, 2026

Industry

Biotechnology

Sector

Health Care

Employees

142

CEO

Arthur Kuan

Website

www.cgoncology.com

Headquarters

Dallas, TX 75247, US

CGON Financials

Key Financial Metrics (TTM)

Gross Margin

-82.69%

Operating Margin

-4056.18%

Net Income Margin

-3602.68%

Return on Equity

-25.20%

Return on Capital

-25.11%

Return on Assets

-20.67%

Earnings Yield

-3.63%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$6.59BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

88.64M

Volume

612.57K

Avg. Volume

983.70K

Financials (TTM)

Gross Profit

-$5.15M

Operating Income

-$252.62M

EBITDA

-$222.27M

Operating Cash Flow

-$178.47M

Capital Expenditure

-$876.00K

Free Cash Flow

-$179.34M

Cash & ST Invst.

$1.03B

Total Debt

$8.82M

Cg Oncology Performance Analysis

Cg Oncology annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 191,000-98.2%
20232023-12-31USD 204,0006.8%
20242024-12-31USD 1,139,000458.3%
20252025-12-31USD 4,040,000254.7%
Cg Oncology sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-3139.4%
Q12026-03-31-53.4%
Q22026-06-306.8%
Cg Oncology annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.66138.2%
20232023-12-31USD -1.0254.8%
20242024-12-31USD -1.1613.6%
20252025-12-31USD -2.0880.2%
Cg Oncology sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-5.6%
Q42025-12-318.8%
Q12026-03-31-36.5%
Q22026-06-30-26.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.16M

N/A

Gross Profit

-$2.77M

+91.2%

Gross Margin

-2.39%

N/A

Market Cap

$6.59BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$46.41M

N/A

Employees

142

N/A

Net Income

-$79.06M

-90.8%

EBITDA

-$79.06M

-91.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$1.03B

+55.6%

Total Debt

$8.82M

+787.2%

Accounts Receivable

$417.00K

-25.8%

Inventory

$1.00M

N/A

Long Term Debt

$7.83M

+1009.6%

Short Term Debt

$985.00K

+242.0%

Return on Assets

-20.67%

N/A

Return on Invested Capital

-24.33%

N/A

Free Cash Flow

-$46.88M

-67.6%

Operating Cash Flow

-$46.41M

-66.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CNTACentessa Pharmaceuticals plc
$40.50+0.00%
TVTXTravere Therapeutics, Inc.
$65.67-2.74%
XENEXenon Pharmaceuticals Inc.
$59.99-3.13%
APGEApogee Therapeutics, Inc.
$134.97+0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$217.55-0.05%
PCGPG&E
$16.60-0.08%
BITOProShares Trust - ProShares Bitcoin ETF
$10.45-0.03%
IRENIren
$35.45-0.13%

Questions About CGON

What is the current price of Cg Oncology?

Cg Oncology is trading at $74.34 per share.

What is the 52-week range for Cg Oncology?

Over the past 52 weeks, Cg Oncology has traded between $26.25 and $80.97.

How much debt does Cg Oncology have?

As of the most recent reporting period, Cg Oncology reported total debt of $8.82M.

How much cash does Cg Oncology have on hand?

Cg Oncology reported $19.64M in cash and cash equivalents in its most recent financial results.

What is Cg Oncology’s dividend yield?

Cg Oncology does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services